Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Prescribing Specialists Confirm Success of Verona Pharma Product Ohtuvayre in Maintaining COPD Treatment

January 7, 2025 0

Verona Pharma Today, January 7, 2024 Verona Pharma (VRNA) announced preliminary unaudited net product sales for …

A Reminder: Verastem Oncology Announced FDA Acceptance and Priority Review of the NDA Avutometinib (in Combination with Defactinib) for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

January 6, 2025 0

Verastem Oncology in the NEWS On December 30, 2024, Verastem Oncology (VSTM) announced that the U.S. …

Vertex Announces US FDA Approval of ALYFTREK™ Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

December 23, 2024 0

Vertex Pharmaceuticals Vertex Pharmaceuticals (VRTX) announced a United States FDA has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily …

Revisiting Bluebird Bio Inc

December 18, 2024 0

Bluebird Bio Inc For investors who thought that bluebird bio Inc (BLUE) stock price jumped up …

Broadcom Inc’s Greatest Day

December 13, 2024 0

Broadcom Inc Q4 Financial Results for Broadcom Inc (AVGO) reported financial results for its fourth quarter …

Novo Nordisk: European Regulatory Authority Adopts Positive Opinion for an Update of Ozempic® Label to Reflect Risk Reduction of Kidney Disease-Related Events

December 12, 2024 0

Novo Nordisk Bagsværd, Denmark, 12 December 2024 – Novo Nordisk (NVO) announced that the European Medicines …

Johnson & Johnson Product CARVYKTI® Improves Standard of Care Therapies for Relapsed or Refractory Multiple Myeloma

December 11, 2024 0

Johnson & Johnson On December 9, 2024, Johnson & Johnson (JNJ) announced new results from the Phase …

At ASH 2024, Gilead Sciences’ Kite’s Yescarta® Shows Its CAR T-Cell Therapy Uniquely Durable Response and Long-Term Survival After Five Years in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas

December 10, 2024 0

Gilead Sciences Kite Pharma, a Gilead Sciences Company (GILD) announced results from a five-year follow-up analysis …

From ASH: Vertex Pharmaceuticals Presented Positive Durability Gene Editing CASGEVY for Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

December 9, 2024 0

Vertex Pharmaceuticals ASH Announcement Today, December 8, 2024, Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY™ …

Intra-Cellular Therapies Submits Supplemental New Drug Application to the US FDA for CAPLYTA® Treatment of Major Depressive Disorder as Adjunctive Therapy

December 6, 2024 0

Intra-Cellular Therapies in the NEWS On December 3, 2024, Intra-Cellular Therapies (ITCI) announced the submission of …

Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its Progression to Phase 2 with Novel, Second-Generation Immunomodulator

December 5, 2024 0

Nuvig Therapeutics in the NEWS Nuvig Therapeutics – a privately held biotech company, developing novel immunomodulatory therapeutics …

Gilead and Tubulis Enter Exclusive Option and License Agreement to Develop Antibody Drug Conjugate That Targets Solid Tumors

December 4, 2024 0

Gilead Sciences and Tubulis Agreement Gilead Sciences (GILD) and Tubulis announced that they entered into an …

Why Keros Therapeutics is Getting $200 Million Upfront Payment and Possibly Future Payments from Takeda That Could Exceed $1.1 Billion and More

December 3, 2024 0

Keros Therapeutics in the NEWS Today, December 3, 2024, Keros Therapeutics (KROS) announced an exclusive global …

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington’s Disease Program

December 2, 2024 0

PTC Therapeutics in the NEWS Today, December 2, 2024, PTC Therapeutics (PTCT) announced the signing of …

AstraZeneca Product Trugap+Abiraterone and Androgen Deprivation Therapy Improved Primary Endpoint of Radiographic PFS in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

November 27, 2024 0

AstraZeneca in the NEWS AstraZeneca (AZN) Phase III trial CAPItello-281, which combines Truqap (capivasertib), abiraterone, and …

The U.S. FDA Approved BridgeBio Pharma Product Attruby to Treat Adults with ATTR-CM to Reduce Cardiovascular Death and Hospitalization

November 25, 2024 0

BridgeBio Pharma in the NEWS BridgeBio Pharma (BBIO) focused on genetic diseases, announced that the United …

Viking Therapeutics Presented Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

November 20, 2024 0

Viking Therapeutics Announcement On Nov. 19, 2024, Viking Therapeutics, Inc. (VKTX) announced that the final results …

Biogen and UCB Results: Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol Demonstrated a Reduction in Systemic Lupus Erythematosus Disease Activity

November 19, 2024 0

Biogen & UCB Announcement Today, November 19, 2024, UCB (Euronext Brussels: (UCB) and Biogen (BIIB) presented …

Intellia Announces First Clinical Evidence from Phase 1 Study That an In Vivo CRISPR/Cas9-Based Gene Editing Therapy May Favorably Impact Disease Progression in Amyloidosis

November 19, 2024 0

Intellia Therapeutics Announcement On Nov. 16, 2024, Intellia Therapeutics (NTLA), a clinical-stage gene editing company focused …

Adaptimmune’s Lete-cel Achieves Primary Endpoint in Pivotal Trial Treating Advanced Sarcomas and Other Solid Cancers

November 15, 2024 0

Adaptimmune Therapeutics Announcement Today, November 13, 2024, Adaptimmune Therapeutics plc (ADAP), a company working to redefine …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Prescribing Specialists Confirm Success of Verona Pharma Product Ohtuvayre in Maintaining COPD Treatment

A Reminder: Verastem Oncology Announced FDA Acceptance and Priority Review of the NDA Avutometinib (in Combination with Defactinib) for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Vertex Announces US FDA Approval of ALYFTREK™ Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

Revisiting Bluebird Bio Inc

Broadcom Inc’s Greatest Day

Novo Nordisk: European Regulatory Authority Adopts Positive Opinion for an Update of Ozempic® Label to Reflect Risk Reduction of Kidney Disease-Related Events

Johnson & Johnson Product CARVYKTI® Improves Standard of Care Therapies for Relapsed or Refractory Multiple Myeloma

At ASH 2024, Gilead Sciences’ Kite’s Yescarta® Shows Its CAR T-Cell Therapy Uniquely Durable Response and Long-Term Survival After Five Years in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas

From ASH: Vertex Pharmaceuticals Presented Positive Durability Gene Editing CASGEVY for Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Intra-Cellular Therapies Submits Supplemental New Drug Application to the US FDA for CAPLYTA® Treatment of Major Depressive Disorder as Adjunctive Therapy

Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its Progression to Phase 2 with Novel, Second-Generation Immunomodulator

Gilead and Tubulis Enter Exclusive Option and License Agreement to Develop Antibody Drug Conjugate That Targets Solid Tumors

Why Keros Therapeutics is Getting $200 Million Upfront Payment and Possibly Future Payments from Takeda That Could Exceed $1.1 Billion and More

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington’s Disease Program

AstraZeneca Product Trugap+Abiraterone and Androgen Deprivation Therapy Improved Primary Endpoint of Radiographic PFS in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

The U.S. FDA Approved BridgeBio Pharma Product Attruby to Treat Adults with ATTR-CM to Reduce Cardiovascular Death and Hospitalization

Viking Therapeutics Presented Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

Biogen and UCB Results: Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol Demonstrated a Reduction in Systemic Lupus Erythematosus Disease Activity

Intellia Announces First Clinical Evidence from Phase 1 Study That an In Vivo CRISPR/Cas9-Based Gene Editing Therapy May Favorably Impact Disease Progression in Amyloidosis

Adaptimmune’s Lete-cel Achieves Primary Endpoint in Pivotal Trial Treating Advanced Sarcomas and Other Solid Cancers